

The Board members met by conference call on Monday, September 30, 2019. President Keith Vance called the meeting to order at 11:00am. Board Members Ashley Duggins, Robert Graves, Dr. Andy Bowman, Bill Mixon, and Gene Minton Present were present. Also present were Executive Director Jay Campbell, Board Counsel Clint Pinyan, Associate Executive Director Ellen Vick, Director of Inspections Krystal Stefyank, Cassandra with Cannon Pharmacy, Denny Barnes, and Joe Cabaleiro.

President Vance read the Ethics Statement regarding any conflicts of interest and/or appearances of conflicts of interest of any Board member. No conflicts were noted by Board members.

Revised Chapters of United States Pharmacopeia (“USP”) on Non-Sterile Compounding <795> and Sterile compounding <797> were set to go into effect on December 1, 2019. On September 23, 2019, USP announced that – as required by USP by-laws – it is postponing the effective date of USP chapters <795> and <797> while appeals for review of these revised chapters are resolved. USP’s announcement does not include chapter <800> which is not subject to an appeal and will go into effect on December 1, 2019

After discussion, it was the consensus of the Board that Board inspections and investigative staff will continue to use the inspection forms and tools mapped to existing USP chapter requirements. Also, Board staff will not begin inspecting for compliance with USP chapter <800> standards in compounding activities on December 1, 2019. Existing chapters <795> and <797> do not incorporate chapter <800>. Revised chapters <795> and <797> do incorporate <800>. Accordingly, Board staff will begin inspecting for compliance with chapter <800> standards at such time as the revised chapters go into effect.

---

Dr. Keith Vance, President

---

Dr. Ashley Duggins, Vice President

---

Dr. Andy Bowman

---

Gene Minton

---

William (Bill) Mixon

---

Robert Graves